Knobbe Martens Olson & Bear LLP

Intellectual Property Law

2040 Main Street Fourteenth Floor Irvine, CA 92614 Tel 949-760-0404 Fax 949-760-9502 www.irmob.com

RECEIVED CENTRAL FAX CENTER

FEB 2 2 2006

FACSIMILE TRANSMITTAL SHEET

CONFIRMATION COPY WILL FOLLOW VIA:

☐ MAIL	■ WILL NOT FOLLOW
☐ INTERNATIONAL AIRMAIL	☐ HAND DELIVERY
☐ COURIER	WITH ENCLOSURES
☐ E-MAIL	■ WITHOUT ENCLOSURES

Confidentiality Notice:

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; and any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited,

To:

Susan Ungar

FIRM:

USPTO

FACSBAILE NO.:

(571)273-0837

OUR REF .:

BOEHM22.001APC

Your Ref.:

10/019,513

FROM:

Che Chereskin

OPERATOR:

Deirdre Bailey

No. Of Pages: 20

(incl. cover sheet)

DATE:

February 22, 2006

TIME:

IF YOU DID NOT RECEIVE ALL OF THE PAGES PLEASE CALL BACK IMMEDIATELY

OPERATOR PHONE No.: (949) 760-0404

FACSIMILE No.: (949) 760-9502

MESSAGE: FOLLOW UP TO TELEPHONE CONVERSATION

2392473 022206

San Diego 619=235-8550 San Francisco 415-954-4114

Los Angeles 310-551-3450 Riverside

San Luis Obispo RN5-547-55RN

RECEIVED CENTRAL FAX CENTER

FEB 2 2 2006

BOEHM2: .001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Brossart, et al.

Appl No.

10/019,513

Filed

August 6, 2002

For

PEPTIDE FOR TRIGGERING AN

IMMUNE REACTION AGAINST

TUMOR CELLS

Examiner ...

Ungar, Susan

Group Art Unit

1642

LETTER

February 22, 2006

Dear Examiner Ungar

Further to our telephone conversation this morning, please find attached an Inventor's Declaration with Exhibits A & B which provide data showing the utility of the claimed invention in the diagnosis of cancer in vitro. As discussed in the Declaration and accompanying Exhibit B (particularly Figure 4), the STAPPVHNV peptide (SEQ ID NO: 1) successfully lysed primary cancer cells.

We gratefully acknowledge the indication that claim 1 is allowable and that claim 2 is also allowable after Examiner's amendment. We respectfully submit, that in view of the attached Declaration and Exhibits A & B, that claims 21, 24, 27, 29, and 31 may be rejoined and allowed.

Please charge any additional fees, including any fees for additional extension of time, or credit overparment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Feb. 22 2006

By: Che Swyden Chereskin, Ph.D.

Registration No. 41,466 Agent of Record

Customer No. 20,995 (949) 760-0404

2392378/032206